StuartGrossmanMD

Professor of Oncology, Professor of Medicine, Professor of Neurological Surgery, Johns Hopkins University School of Medicine; Medicine and Neurological Surgery, Professor of Oncology

Join to view full profile

Dr. Grossman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Grossman's full profile

Already have an account?

Office
401 N. Broadway
Baltimore, MD 21231
Phone+1 410-955-8964

Fax+1 410-614-9335
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1979 - 1981
University of RochesterResidency, Internal Medicine, 1973 - 1976
University of Rochester School of Medicine and DentistryClass of 1973

Certifications & Licensure

VA State Medical License 2023 - 2026
MD State Medical License 1979 - 2024
PA State Medical License 2020 - 2022
WI State Medical License 1976 - 1978
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2007-2014
America's Top Doctors for Cancer Castle Connolly, 2006-2013
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Join now to see all

Clinical Trials

Procarbazine in Treating Patients With Recurrent Brain Tumor Start of enrollment: 1999 Jul 01
Completed
Phase 1, Phase 2
Karenitecin in Treating Patients With Recurrent Malignant Glioma Start of enrollment: 2002 Jan 01
Completed
Phase 1
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Start of enrollment: 2003 Oct 01
Terminated
Phase 2
High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2005 Jul 12
Completed
Phase 2
Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2005 Feb 15
Terminated
Phase 2
Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas Start of enrollment: 2005 Apr 01
Completed
Modafinil in Opioid Induced Sedation Start of enrollment: 2006 Jan 01
Terminated
Phase 3
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Start of enrollment: 2006 Oct 12
Completed
Phase 1
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma Start of enrollment: 2007 Jan 01
Completed
Phase 1, Phase 2
Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma Start of enrollment: 2004 May 01
Completed
Not Applicable
Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy Start of enrollment: 2006 Nov 11
Terminated
Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy Start of enrollment: 2008 May 07
Completed
Not Applicable
Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant Glioma Start of enrollment: 2005 Apr 01
Completed
Not Applicable
Studying Fentanyl in Patients With Cancer Start of enrollment: 2007 Oct 01
Terminated
Low Dose Radiation Therapy for Glioblastoma Multiforme Start of enrollment: 2012 Sep 01
Completed
Phase 2
Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas Start of enrollment: 2012 Jul 13
Completed
Not Applicable
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30
Terminated
Phase 1
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) Start of enrollment: 2016 Oct 25
Recruiting
Phase 1
A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas Start of enrollment: 2018 May 19
Terminated
Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas Start of enrollment: 2019 Dec 06
Terminated
Phase 1
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG Start of enrollment: 2019 Jul 29
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Clinical trials of R-(-)-gossypol (AT-101) in newly diagnosed and recurrent glioblastoma: NABTT 0602 and NABTT 0702.
Ye, X., Peerboom, D., Mikkelsen, T., Lesser, G., Fisher, J., Desideri, S., Leopold, L., Fiveash, J., Chowdhary, S., Rosenfeld, M., Grossman, S., Nabors, L.> ;Plos One. 2024 Jan 1
A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).
Lawrence Kleinberg, Xiaobu Ye, Jeff Supko, Glen H J Stevens, Hui-Kuo Shu, Tom Mikkelsen, Frank Lieberman, Glenn J Lesser, Emerson Lee, Stuart A Grossman> ;Journal of Neuro-Oncology. 2023 Dec 1
2 citations
Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
Roy Strowd, Benjamin Ellingson, Catalina Raymond, Jingwen Yao, Patrick Y Wen, Manmeet Ahluwalia, Anna Piotrowski, Arati Desai, Jennifer L Clarke, Frank S Lieberman, Se...> ;Journal of Neuro-Oncology. 2023 Oct 1
1 citations
CEST2022: Amide proton transfer-weighted MRI improves the diagnostic performance of multiparametric non-contrast-enhanced MRI techniques in patients with post-treatmen...
Qianqi Huang, Jingpu Wu, Nhat Le, Yiqing Shen, Pengfei Guo, Karisa C Schreck, David Kamson, Lindsay Blair, Hye-Young Heo, Xu Li, Wenbo Li, Haris L Sair, Jaishri O Blak...> ;Magnetic Resonance Imaging. 2023 Oct 1
Using historical objective response rates to design single-arm phase II trials in patients with recurrent glioblastoma.
Stuart A Grossman> ;Neuro-Oncology. 2023 Jun 2
1 citations
Druggable genomic landscapes of high-grade gliomas.
Ghanem, P., Fatteh, M., Kamson, D., Balan, A., Chang, M., , Tao, J., Blakeley, J., Canzoniero, J., Grossman, S., Marrone, K., Schreck, K., Anagnostou, V.> ;Frontiers in Medicine. 2023 Jan 1
2 citations
magnetic resonance spectroscopy of lactate as a non-invasive biomarker of dichloroacetate activity in cancer and non-cancer central nervous system disorders.
David O Kamson, Viveka Chinnasamy, Stuart A Grossman, Chetan Bettegowda, Peter B Barker, Peter W Stacpoole, Georg Oeltzschner> ;Frontiers in Oncology. 2023 Jan 1
2 citations
ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449.
Andrew E Sloan, Charles J Nock, Xiaobu Ye, Robert Buerki, Susan Chang, Glenn Lesser, Andrew Norden, Timothy Cloughesy, Jeffrey Olson, Amber Kerstetter-Fogle, Jeremy Ri...> ;Journal of Neuro-Oncology. 2023 Jan 1
3 citations
Evidence for Persistent Radiation-Related Injury to the Immune System in Patients With Local Breast Cancer.
Janhavi Athale, Kristen Broderick, Xiaojun Wu, Stuart Grossman> ;International Journal of Radiation Oncology, Biology, Physics. 2023 Apr 1
Safety of temozolomide use in adult patients with renal dysfunction.
Kayla Garzio, Kelly McElroy, Stuart Grossman, Matthias Holdhoff, Byram Ozer, Olga Yankulina> ;Journal of Neuro-Oncology. 2022 Sep 1
5 citations
Lymphocyte Depletion Rate as a Biomarker of Radiation Dose to Circulating Lymphocytes During Fractionated Partial-Body Radiation Therapy.
Susannah G Ellsworth, Anirudh Yalamanchali, Tim Lautenschlaeger, Stuart A Grossman, Clemens Grassberger, Steven H Lin, Radhe Mohan> ;Advances in Radiation Oncology. 2022 Apr 8
3 citations
High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes.
Xiaobu Ye, Karisa C Schreck, Byram H Ozer, Stuart A Grossman> ;Expert Review of Anticancer Therapy. 2022 Mar 1
Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Matthew A Smith-Cohn, Nicholas B Burley, Stuart A Grossman> ;Current Neuropharmacology. 2022 Jan 1
46 citations
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.
Stephen J Bagley, Shawn Kothari, Rifaquat Rahman, Eudocia Q. Lee, Gavin P. Dunn, Evanthia Galanis, Susan M. Chang, Louis B. Nabors, Manmeet S Ahluwalia, Roger Stupp, M...> ;Clinical Cancer Research. 2021 Sep 24
5 citations
Multimodal platform for assessing drug distribution and response in clinical trials.
Begoña Gimenez-Cassina Lopez, Ishwar N. Kohale, Ziming Du, Ilya Korsunsky, Walid M. Abdelmoula, Yang Dai, Sylwia A. Stopka, Giorgio Gaglia, Elizabeth C. Randall, Micha...> ;Neuro-Oncology. 2021 Aug 12
13 citations
The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic.
David O. Kamson, Stuart A. Grossman> ;JAMA Oncology. 2021 May 1
8 citations
Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies
Anirudh Yalamanchali, Hong Zhang, Ke Colin Huang, Radhe Mohan, Steven H. Lin, Cong Zhu, Stuart A. Grossman, Jian Yue Jin, Susannah G. Ellsworth> ;Advances in Radiation Oncology. 2021 Jan 1
10 citations
Adult precision medicine: learning from the past to enhance the future
Ashley Ghiaseddin, Lan B Hoang Minh, Michalina Janiszewska, David Shin, Wolfgang Wick, Duane Mitchell, Patrick Y. Wen, Stuart A. Grossman> ;Neuro-Oncology Advances. 2021 Jan 1
1 citations
The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returns.
Stuart A. Grossman> ;Neuro-Oncology. 2020 Dec 18
17 citations
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first worksh...
Stuart A. Grossman, Carlos Romo, Michelle A. Rudek, Jeffrey G. Supko, Joy D. Fisher, L. Burt Nabors, Patrick Y. Wen, David M. Peereboom, Benjamin M. Ellingson, William...> ;Neuro-Oncology. 2020 Oct 1
14 citations
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
David M. Peereboom, Xiaobu Ye, Tom Mikkelsen, Glenn J. Lesser, Frank S. Lieberman, H. Ian Robins, Manmeet Ahluwalia, Andrew E. Sloan, Stuart A. Grossman> ;Neurosurgery. 2021 Jan 13
4 citations
Quantifying the utility of a multidisciplinary neuro-oncology tumor board.
Adham M. Khalafallah, Adrian E. Jimenez, Carlos G Romo, David O. Kamson, Lawrence Kleinberg, Jon D. Weingart, Henry Brem, Stuart A. Grossman, Debraj Mukherjee> ;Journal of Neurosurgery. 2020 Sep 18
35 citations
Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome.
Brij S Karmur, Justine Philteos, Aram Abbasian, Brad E. Zacharia, Nir Lipsman, Victor A. Levin, Stuart A. Grossman, Alireza Mansouri> ;Frontiers in Oncology. 2020 Sep 18
4 citations
RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events.
Karisa C. Schreck, Mallika P Patel, Jan Wemmer, Stuart A. Grossman, Katherine B. Peters> ;Neuro-Oncology Practice. 2020 Jul 31
41 citations
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Kurt A. Jaeckle, Karla V. Ballman, Martin J. van den Bent, Caterina Giannini, Evanthia Galanis, Paul D. Brown, Robert B. Jenkins, J. Gregory Cairncross, Wolfgang Wick,...> ;Neuro-Oncology. 2021 Mar 25
Join now to see all

Journal Articles

The Role of Temozolomide in Patients with Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic
Stuart Grossman, MD, JAMA Oncology